QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:ATEC

Alphatec Stock Forecast, Price & News

$16.46
+0.37 (+2.30 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.20
Now: $16.46
$16.92
50-Day Range
$13.13
MA: $15.08
$16.67
52-Week Range
$2.19
Now: $16.46
$17.20
Volume503,356 shs
Average Volume598,618 shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to meet the surgeon's needs and to maximize patient outcomes; LLICO access system, a minimally invasive posterior thoracolumbar access system; Invictus Spinal Fixation System, a comprehensive thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep designed to improve surgical efficiency without compromising accuracy. It also provides Arsenal spinal fixation system intended for posterior, non-cervical fixation in skeletally mature patients for treating degenerative disc disease, spondylolisthesis, fracture or dislocation, spinal stenosis, curvatures, tumor, pseud arthrosis, and failed previous fusion; zodiac degenerative spinal fixation system, a comprehensive spinal system used to address degenerative spinal conditions and deformity correction; OsseoScrew system to restore the integrity of the spinal column; trestle luxe anterior cervical plate system; and solanas posterior cervico/thoracic fixation system and avalon occipital plate. In addition, the company offers IdentiTi Porous Ti and Transcend Lateral Interbody Implants; Battalion PC; Novel SD; Solus Anterior Lumbar Interbody Fusion System. Further, it is developing EOS imaging products. Additionally, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Alphatec logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATEC
CUSIP02081G10
Phone760-431-9286
Employees227
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$113.43 million
Book Value$0.71 per share

Profitability

Net Income$-57,000,000.00

Miscellaneous

Market Cap$1.29 billion
Next Earnings Date3/4/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.83 out of 5 stars

Medical Sector

1130th out of 1,958 stocks

Surgical & Medical Instruments Industry

106th out of 168 stocks

Analyst Opinion: 1.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$16.46
+0.37 (+2.30 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alphatec (NASDAQ:ATEC) Frequently Asked Questions

Is Alphatec a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alphatec stock.
View analyst ratings for Alphatec
or view top-rated stocks.

What stocks does MarketBeat like better than Alphatec?

Wall Street analysts have given Alphatec a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alphatec wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Alphatec's next earnings date?

Alphatec is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Alphatec
.

How can I listen to Alphatec's earnings call?

Alphatec will be holding an earnings conference call on Thursday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) issued its earnings results on Thursday, November, 5th. The medical technology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.01. The medical technology company had revenue of $41.16 million for the quarter, compared to analysts' expectations of $40.83 million. Alphatec had a negative net margin of 51.95% and a negative trailing twelve-month return on equity of 266.45%.
View Alphatec's earnings history
.

How has Alphatec's stock been impacted by COVID-19?

Alphatec's stock was trading at $4.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ATEC stock has increased by 273.2% and is now trading at $16.46.
View which stocks have been most impacted by COVID-19
.

What guidance has Alphatec issued on next quarter's earnings?

Alphatec issued an update on its fourth quarter 2020 IntraDay earnings guidance on Tuesday, January, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $43.8-44.1 million, compared to the consensus revenue estimate of $43.66 million.

What price target have analysts set for ATEC?

7 analysts have issued twelve-month target prices for Alphatec's shares. Their forecasts range from $9.00 to $20.00. On average, they expect Alphatec's share price to reach $14.71 in the next year. This suggests that the stock has a possible downside of 10.6%.
View analysts' price targets for Alphatec
or view top-rated stocks among Wall Street analysts.

Who are Alphatec's key executives?

Alphatec's management team includes the following people:
  • Mr. Patrick S. Miles, Exec. Chairman, CEO & Pres (Age 55, Pay $1.23M)
  • Mr. Jeffrey G. Black, Exec. VP & CFO (Age 52, Pay $652.76k)
  • Mr. David P. Sponsel, Exec. VP of Sales (Age 42, Pay $768.18k)
  • Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 57)
  • Mr. Brian R. Snider, Exec. VP of Marketing & Devel. (Age 43)
  • Mr. Jonathan Allen, Exec. VP of Commercial Operations (Age 61)
  • Dr. Luiz Pimenta, Chief Medical Officer
  • Ms. Kelli Mari Howell, Exec. VP of Clinical Strategies (Age 47)
  • Mr. Mark D. Ojeda, Exec. VP of Cervical & Biologics (Age 51)
  • Mr. Eric Dasso, Exec. VP of Adjunctive Technologies (Age 48)

What is Pat Miles' approval rating as Alphatec's CEO?

7 employees have rated Alphatec CEO Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among Alphatec's employees.

Who are some of Alphatec's key competitors?

What other stocks do shareholders of Alphatec own?

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Who are Alphatec's major shareholders?

Alphatec's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.00%), Cerity Partners LLC (3.06%), Avidity Partners Management LP (2.36%), Next Century Growth Investors LLC (2.15%), Price T Rowe Associates Inc. MD (1.46%) and Royce & Associates LP (1.17%). Company insiders that own Alphatec stock include Craig E Hunsaker, David Sponsel, Evan Bakst, James L L Tullis, Jeffrey G Black, Jeffrey P Rydin and Kelli Mari Howell.
View institutional ownership trends for Alphatec
.

Which major investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Russell Investments Group Ltd., Parian Global Management LP, LPL Financial LLC, Essex Investment Management Co. LLC, Royce & Associates LP, Alliancebernstein L.P., and JPMorgan Chase & Co.. Company insiders that have sold Alphatec company stock in the last year include Craig E Hunsaker, David Sponsel, James L L Tullis, and Jeffrey G Black.
View insider buying and selling activity for Alphatec
or view top insider-selling stocks.

Which major investors are buying Alphatec stock?

ATEC stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Price T Rowe Associates Inc. MD, Next Century Growth Investors LLC, BlackRock Inc., Pier Capital LLC, Columbus Circle Investors, Nuveen Asset Management LLC, and Morgan Stanley. Company insiders that have bought Alphatec stock in the last two years include David Sponsel, Evan Bakst, and Kelli Mari Howell.
View insider buying and selling activity for Alphatec
or or view top insider-buying stocks.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $16.46.

How much money does Alphatec make?

Alphatec has a market capitalization of $1.29 billion and generates $113.43 million in revenue each year. The medical technology company earns $-57,000,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does Alphatec have?

Alphatec employs 227 workers across the globe.

What is Alphatec's official website?

The official website for Alphatec is www.atecspine.com.

Where are Alphatec's headquarters?

Alphatec is headquartered at 5818 EL CAMINO REAL, CARLSBAD CA, 92008.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at 760-431-9286 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.